The Incredible Dividend Map... Where Stocks Yield 26% a Year!

From Investing Daily | Ad

What’s the highest-yielding stock you’ve ever owned?

The dividends for these stocks have risen so fast over the years that they’re now yielding us an average of 26%!

When you start getting paid 26% on your money, your financial problems tend to pretty much evaporate.

Get in on the action here.

ORTX Insider Trading (Orchard Therapeutics)

Insider Trading Chart
Insider Trading History
Frequently Asked Questions
About

Insider Ownership Percentage: 2.40%

Insider Buying (Last 12 Months): $18,600.00

Insider Selling (Last 12 Months): $0.00

Orchard Therapeutics Insider Trading History Chart

Orchard Therapeutics Share Price & Price History

^$0.48

+0.30 (1.20%)

As of 05/18/2022 05:00 PM ET

Days: 30 | 90 | 365

High Arch Potential Stock

From Wealthy Millionaire | Ad

If you're looking for a hot new sector, watch this stock closely.

Click for ticker & full details

Orchard Therapeutics Insider Trading History

Transaction Date	Insider Name	Title	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction
4/1/2022	Bobby Gaspar	CEO	Buy	15,000	$0.74	$11,100.00	366,158
4/1/2022	Frank E Thomas	Insider	Buy	10,000	$0.75	$7,500.00	52,081
2/5/2021	Fmr Llc	Insider	Sell	2,045,510	$6.98	$14,277,659.80
1/2/2020	Fmr Llc	Insider	Sell	19,721	$13.49	$266,036.29

Warning: The Last Value Play Gone After August?

From Oxford Club | Ad

In this market...There's ONE STOCK (priced at just under $2) that could be $20 and STILL be a bargain. It brought in more income – including equity sales - in the last 12 months than Disney, Square or Tesla.

But a key announcement in August could send this stock rocketing skyward

Get the Details Now.

SEC Filings (Institutional Ownership Changes) for Orchard Therapeutics (NASDAQ:ORTX)

56.47% of Orchard Therapeutics stock is owned by institutions. Institutional ownership can be a sign of analyst confidence in the fundamentals of the stock.

Institutional Buying and Selling by Quarter

Orchard Therapeutics Institutional Trading History

Reporting Date	Hedge Fund	Shares Held	Market Value	% of Portfolio	Quarterly Change in Shares	Ownership in Company
5/16/2022	Goldman Sachs Group Inc.	36,794	$26K	0.0%	-49.8%	0.029%
5/13/2022	Renaissance Technologies LLC	814,025	$0.58M	0.0%	-16.6%	0.647%
5/13/2022	Sei Investments Co.	84,280	$60K	0.0%	-53.5%	0.067%
5/12/2022	BlackRock Inc.	749,990	$0.53M	0.0%	+19.9%	0.596%
5/11/2022	JPMorgan Chase & Co.	1,702,364	$1.21M	0.0%	-7.7%	1.352%
5/11/2022	GSA Capital Partners LLP	374,276	$0.27M	0.0%	+10.5%	0.297%
5/9/2022	Forefront Analytics LLC	99,741	$72K	0.0%	+89.7%	0.079%
5/5/2022	New York State Common Retirement Fund	323,397	$0.23M	0.0%	-66.2%	0.257%
4/29/2022	SG Americas Securities LLC	1,052,786	$0.75M	0.0%	+62.0%	0.837%
4/28/2022	Harbor Capital Advisors Inc.	236,681	$0.17M	0.1%	-14.2%	0.188%
2/23/2022	BlackRock Inc.	625,512	$0.83M	0.0%	-4.2%	0.498%
2/17/2022	Goldman Sachs Group Inc.	73,332	$97K	0.0%	+134.0%	0.058%
2/15/2022	Sei Investments Co.	181,396	$0.24M	0.0%	+18.1%	0.145%
2/15/2022	Legal & General Group Plc	81,422	$0.11M	0.0%	+40.7%	0.065%
2/15/2022	Marshall Wace LLP	23,547	$31K	0.0%	-85.0%	0.019%
2/15/2022	Millennium Management LLC	142,992	$0.19M	0.0%	-65.3%	0.114%
2/14/2022	State Street Corp	106,442	$0.14M	0.0%	-34.7%	0.085%
2/14/2022	Goldman Sachs Group Inc.	73,332	$97K	0.0%	+134.0%	0.058%
2/14/2022	Eversept Partners LP	419,581	$0.55M	0.0%	-26.3%	0.334%
2/14/2022	GSA Capital Partners LLP	338,756	$0.45M	0.1%	-9.6%	0.270%
2/11/2022	Renaissance Technologies LLC	976,005	$1.29M	0.0%	-8.3%	0.778%
2/10/2022	JPMorgan Chase & Co.	1,843,634	$2.43M	0.0%	-42.7%	1.469%
2/10/2022	Acadian Asset Management LLC	108,165	$0.14M	0.0%	N/A	0.086%
2/7/2022	SG Americas Securities LLC	649,670	$0.86M	0.0%	N/A	0.518%
2/4/2022	Harbor Capital Advisors Inc.	275,870	$0.36M	0.1%	N/A	0.220%
2/2/2022	New York State Common Retirement Fund	956,258	$1.26M	0.0%	-26.7%	0.762%
11/16/2021	Jane Street Group LLC	12,597	$29K	0.0%	N/A	0.010%
11/16/2021	Squarepoint Ops LLC	33,030	$76K	0.0%	+65.2%	0.026%
11/16/2021	UBS Group AG	13,671	$31K	0.0%	-73.8%	0.011%
11/16/2021	Millennium Management LLC	411,713	$0.95M	0.0%	+1,740.2%	0.328%
11/16/2021	Casdin Capital LLC	2,575,000	$5.92M	0.1%	-19.9%	2.054%
11/15/2021	Cubist Systematic Strategies LLC	17,572	$40K	0.0%	N/A	0.014%
11/15/2021	Marshall Wace LLP	157,194	$0.36M	0.0%	N/A	0.125%
11/15/2021	RA Capital Management L.P.	11,028,722	$25.37M	0.4%	-10.4%	8.797%
11/15/2021	Morgan Stanley	148,798	$0.34M	0.0%	+74.2%	0.119%
11/15/2021	Farallon Capital Management LLC	665,200	$1.53M	0.0%	-79.3%	0.531%
11/15/2021	Eversept Partners LP	569,581	$1.31M	0.1%	N/A	0.454%
11/15/2021	GSA Capital Partners LLP	374,811	$0.86M	0.1%	N/A	0.299%
11/12/2021	Renaissance Technologies LLC	1,064,379	$2.45M	0.0%	+964.4%	0.849%
11/12/2021	Jump Financial LLC	68,000	$0.16M	0.0%	+20.5%	0.054%
11/12/2021	Hennion & Walsh Asset Management Inc.	183,346	$0.42M	0.0%	-4.7%	0.146%
11/12/2021	Artisan Partners Limited Partnership	10,846,420	$24.95M	0.0%	-19.3%	8.651%
11/10/2021	Citigroup Inc.	142,755	$0.33M	0.0%	+20.5%	0.114%
11/10/2021	Rafferty Asset Management LLC	652,007	$1.50M	0.0%	-9.5%	0.520%
11/9/2021	BlackRock Inc.	652,833	$1.50M	0.0%	-3.4%	0.521%
11/9/2021	Platinum Investment Management Ltd.	1,078,315	$2.48M	0.1%	+43.4%	0.860%
11/5/2021	Daiwa Securities Group Inc.	13,257	$30K	0.0%	+9,867.7%	0.011%
8/23/2021	Morgan Stanley	85,431	$0.38M	0.0%	+368.7%	0.068%
8/18/2021	Ikarian Capital LLC	150,000	$0.66M	0.1%	-40.0%	0.120%
8/17/2021	Itau Unibanco Holding S.A.	7,825	$34K	0.0%	N/A	0.006%
8/17/2021	Millennium Management LLC	22,373	$98K	0.0%	-92.6%	0.018%
8/17/2021	Price T Rowe Associates Inc. MD	1,342,858	$5.90M	0.0%	-0.5%	1.071%
8/17/2021	Boothbay Fund Management LLC	46,874	$0.21M	0.0%	-11.7%	0.037%
8/16/2021	Squarepoint Ops LLC	19,998	$88K	0.0%	-70.8%	0.016%
8/16/2021	Bank of America Corp DE	9,281	$41K	0.0%	-78.5%	0.007%
8/16/2021	Morgan Stanley	85,431	$0.38M	0.0%	+368.7%	0.068%
8/16/2021	State Street Corp	102,832	$0.45M	0.0%	-51.2%	0.082%
8/16/2021	Goldman Sachs Group Inc.	27,805	$0.12M	0.0%	+21.2%	0.022%
8/13/2021	Renaissance Technologies LLC	100,000	$0.44M	0.0%	N/A	0.080%
8/13/2021	Northern Trust Corp	26,049	$0.11M	0.0%	-41.0%	0.021%
8/13/2021	Jump Financial LLC	56,454	$0.25M	0.0%	N/A	0.045%
8/13/2021	QS Investors LLC	108,000	$0.48M	0.0%	+730.8%	0.086%
8/13/2021	Qube Research & Technologies Ltd	94,492	$0.42M	0.0%	N/A	0.075%
8/13/2021	Vident Investment Advisory LLC	43,810	$0.19M	0.0%	N/A	0.035%
8/13/2021	IPG Investment Advisors LLC	14,100	$62K	0.0%	N/A	0.011%
8/13/2021	ProShare Advisors LLC	12,007	$53K	0.0%	N/A	0.010%
8/12/2021	Legal & General Group Plc	50,510	$0.22M	0.0%	-20.9%	0.040%
8/12/2021	JPMorgan Chase & Co.	4,837,859	$21.24M	0.0%	+4.4%	3.859%
8/12/2021	Artisan Partners Limited Partnership	13,443,032	$59.02M	0.1%	+26.3%	10.723%
8/11/2021	CHI Advisors LLC	4,081,972	$17.92M	4.2%	+0.7%	3.256%
8/11/2021	BlackRock Inc.	675,716	$2.97M	0.0%	+28.1%	0.539%
8/11/2021	Lord Abbett & CO. LLC	1,626,603	$7.14M	0.0%	-8.1%	1.297%
8/11/2021	Banque Cantonale Vaudoise	16,500	$73K	0.0%	+57.1%	0.013%
8/10/2021	Virtus ETF Advisers LLC	44,471	$0.20M	0.1%	-32.6%	0.035%
8/10/2021	Citigroup Inc.	118,483	$0.52M	0.0%	+234.7%	0.095%
8/10/2021	Rafferty Asset Management LLC	720,818	$3.16M	0.0%	+8.1%	0.575%
8/6/2021	Mutual of America Capital Management LLC	236,817	$1.04M	0.0%	-4.1%	0.191%
8/6/2021	Sei Investments Co.	195,545	$0.86M	0.0%	+71.7%	0.158%
8/6/2021	Mitsubishi UFJ Kokusai Asset Management Co. Ltd.	55,626	$0.24M	0.0%	-32.5%	0.045%
8/5/2021	Fox Run Management L.L.C.	10,247	$45K	0.0%	N/A	0.008%
8/3/2021	Victory Capital Management Inc.	77,236	$0.34M	0.0%	-4.7%	0.062%
8/2/2021	Chicago Partners Investment Group LLC	17,678	$52K	0.0%	N/A	0.014%
5/19/2021	Copernicus Capital Management LLC	15,000	$0.11M	1.8%	N/A	0.012%
5/19/2021	Squarepoint Ops LLC	68,472	$0.50M	0.0%	-15.7%	0.057%
5/18/2021	Baker BROS. Advisors LP	734,431	$5.33M	0.0%	+120.9%	0.609%
5/18/2021	Millennium Management LLC	303,524	$2.20M	0.0%	+103.5%	0.252%
5/18/2021	Morgan Stanley	18,226	$0.13M	0.0%	-96.8%	0.015%
5/17/2021	Woodline Partners LP	56,297	$0.41M	0.0%	-92.3%	0.047%
5/17/2021	Ameriprise Financial Inc.	67,701	$0.49M	0.0%	-15.7%	0.056%
5/17/2021	Hennion & Walsh Asset Management Inc.	185,220	$1.35M	0.1%	N/A	0.154%
5/17/2021	HRT Financial LP	23,161	$0.17M	0.0%	N/A	0.019%
5/17/2021	Sphera Funds Management LTD.	1,366,564	$9.92M	0.8%	N/A	1.134%
5/17/2021	Ikarian Capital LLC	250,000	$1.82M	0.1%	N/A	0.207%
5/17/2021	Goldman Sachs Group Inc.	22,943	$0.17M	0.0%	-92.1%	0.019%
5/14/2021	TD Asset Management Inc.	35,109	$0.26M	0.0%	+38.4%	0.029%
5/13/2021	QS Investors LLC	13,000	$95K	0.0%	N/A	0.011%
5/13/2021	Mutual of America Capital Management LLC	247,007	$1.79M	0.0%	-5.2%	0.205%
5/13/2021	Forefront Analytics LLC	16,110	$0.12M	0.1%	-49.8%	0.013%
5/13/2021	Citigroup Inc.	35,401	$0.26M	0.0%	+74.6%	0.029%
5/13/2021	Massachusetts Financial Services Co. MA	501,739	$3.64M	0.0%	-2.3%	0.416%

Data available starting January 2016

Orchard Therapeutics plc, a biopharmaceutical company, develops gene therapies for serious and life-threatening rare diseases in the United Kingdom, European Union, and the United States. The company's gene therapy approach seeks to transform a patient's hematopoietic stem cells into a gene-modified cellular drug product to treat the patient's disease through a single administration. It provides Strimvelis, a gammaretroviral-based product for the treatment of adenosine deaminase-severe combined immunodeficiency (ADA-SCID). The company's clinical development products comprise OTL-101 for the treatment of ADA-SCID; OTL-200 to treat metachromatic leukodystrophy; OTL-103 for the treatment of Wiskott-Aldrich syndrome; OTL-102 for X-linked chronic granulomatous disease; and OTL-300 for transfusion-dependent beta-thalassemia. Its preclinical programs include OTL-203 for mucopolysaccharidosis type I, OTL-201 for mucopolysaccharidosis type MPS-IIIA, and OTL-202 for mucopolysaccharidosis type IIIB. It has a strategic collaboration agreement with Pharming Group N.V. for research, development, manufacturing, and commercialization of OTL-105, an investigational ex vivo autologous hematopoietic stem cell gene therapy for the treatment of hereditary angioedema. The company was formerly known as Orchard Rx Limited. Orchard Therapeutics plc was founded in 2015 and is headquartered in London, the United Kingdom.

Today's Range

Now: $0.48

$0.46

$0.48

50 Day Range

MA: $0.66

$0.42

$0.85

52 Week Range

Now: $0.48

$0.41

$5.69

Volume

446,216 shs

Average Volume

625,990 shs

Market Capitalization

$60.43 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.19

Who are the company insiders with the largest holdings of Orchard Therapeutics?: Orchard Therapeutics' top insider shareholders include:
Bobby Gaspar (CEO)
Frank E Thomas (Insider)
Fmr Llc (Insider)
Learn More about top insider investors at Orchard Therapeutics.
Who are the major institutional investors of Orchard Therapeutics?: Orchard Therapeutics' top institutional investors include:
JPMorgan Chase & Co. — 1.35%
SG Americas Securities LLC — 0.84%
Renaissance Technologies LLC — 0.65%
BlackRock Inc. — 0.60%
GSA Capital Partners LLP — 0.30%
New York State Common Retirement Fund — 0.26%
Learn More about top institutional investors of Orchard Therapeutics stock.
Which institutional investors are selling Orchard Therapeutics stock?: In the previous quarter, ORTX stock was sold by these institutional investors:
New York State Common Retirement Fund
Renaissance Technologies LLC
JPMorgan Chase & Co.
Sei Investments Co.
Group One Trading L.P.
Harbor Capital Advisors Inc.
Goldman Sachs Group Inc.
Simplex Trading LLC
Which institutional investors are buying Orchard Therapeutics stock?: Within the last quarter, ORTX stock was bought by institutional investors including:
SG Americas Securities LLC
BlackRock Inc.
Forefront Analytics LLC
GSA Capital Partners LLP
Within the last year, these company insiders have bought Orchard Therapeutics stock:
Bobby Gaspar (CEO)
Frank E Thomas (Insider)
Learn More investors buying Orchard Therapeutics stock.

Nevada Desert more Valuable than Wall Street or Silicon Valley?

From Investing Trends | Ad

It could be true, according to Nevada Governor Steve Sisolak. The state's desert flats contain more lithium than any other geography in the world. And with electric vehicles driving a global boom in demand for lithium-ion batteries, Nevada should be on every investor's radar.

Find Out How to Take Advantage of Nevada's Lithium